Intelligence Feed event · Equity · 2026-10-07

    Vaxcyte Prices $1.0B Dual-Tranche Public Equity and Convertible Offering

    Question

    Vaxcyte Prices $1.0B Dual-Tranche Public Equity and Convertible Offering

    Direct answer

    Vaccine developer Vaxcyte raised $1.0 billion via two concurrent offerings: a $500M common equity sale of 7.4 million shares at $64.00 each, and $500 million in 2032 convertible senior notes with a 1.50% coupon. The capital extension secures runway for advanced clinical pipeline assets. Market dynamics around convertible bond pricing frequently induce dealer short selling to establish delta-neutral hedges, adding near-term volume pressure around the $64.00 reference level.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Vaxcyte Prices $1.0B Dual-Tranche Public Equity and Convertible Offering”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/vaxcyte-prices-1-0b-dual-tranche-public-equity-and-convertible-offering-ef14e0

    EQUITY
    Vaxcyte Prices $1.0B Dual-Tranche Public Equity and Convertible Offering
    Vaccine developer Vaxcyte raised $1.0 billion via two concurrent offerings: a $500M common equity sale of 7.4 million shares at $64.00 each, and $500 million in 2032 convertible senior notes with a 1.50% coupon. The capital extension secures runway for advanced clinical pipeline assets. Market dynamics around convertible bond pricing frequently induce dealer short selling to establish delta-neutral hedges, adding near-term volume pressure around the $64.00 reference level.
    PCVX
    Impact
    70
    OCT 7
    SIG
    95%
    PCVX
    Vaxcyte Prices $1.0B Dual-Tranche Public Equity and Convertible Offering
    Vaccine developer Vaxcyte raised $1.0 billion via two concurrent offerings: a $500M common equity sale of 7.4 million shares at $64.00 each, and $500 million in 2032 convertible senior notes with a 1.50% coupon. The capital extension secures runway for advanced clinical pipeline assets. Market dynamics around convertible bond pricing frequently induce dealer short selling to establish delta-neutral hedges, adding near-term volume pressure around the $64.00 reference level.
    → Primary equity issuance at $64.00 per share introduces immediate supply dilution on PCVX, while the 1.50% convertible notes trigger delta-hedging short sales by convertible arbitrage desks.
    Impact
    Vaccine developer Vaxcyte raised $1.0 billion via two concurrent offerings: a $500M common equity sale of 7.4 million shares at $64.00 each, and $500 million in 2032 convertible senior notes with a 1.50% coupon. The capital extension secures runway for advanced clinical pipeline assets. Market dynamics around convertible bond pricing frequently induce dealer short selling to establish delta-neutral hedges, adding near-term volume pressure around the $64.00 reference level.
    Affected
    PCVX
    Transmission
    Primary equity issuance at $64.00 per share introduces immediate supply dilution on PCVX, while the 1.50% convertible notes trigger delta-hedging short sales by convertible arbitrage desks.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    PCVXequity supply dilution and convertible arbitrage delta hedgingMixed1-5dVaxcyte announced pricing for $1B gross proceeds offerings: 7.4M shares at $64.00 and $500M convertible notes.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    PCVXMixed66.96 2026-10-07-2.90%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month